Saved Results

No results saved yet.

Enter a patient name and hit Save on a result.

Clinical calculator summary

CARG Chemotherapy Toxicity Score

The original 11-item additive model stratifying observed grade 3-5 cytotoxic chemotherapy toxicity in older adults with solid tumors.

Evidence-based context for fast calculator use

Purpose:
Support prechemotherapy toxicity discussion alongside comprehensive geriatric assessment
Population:
Adults aged 65 years or older with a solid tumor who are starting a new cytotoxic chemotherapy regimen
Factors:
Age, Cancer type, Planned dose, Number of chemotherapy drugs, Hemoglobin, Jelliffe creatinine clearance using ideal weight, Hearing, Falls, Walking one block, Medication management, Social activity
Reference:
Hurria et al., J Clin Oncol. 2011; external validation 2016
HomeCARG Toxicity Score (Geriatric)
Pin your most used calculators here by clicking the star in the dropdown.

CARG Toxicity Score (Geriatric)

The original general CARG model begins at age 65.

Use the source-defined Jelliffe estimate with ideal weight; do not substitute a different renal equation.

Clinical Context & Background

The original general Cancer and Aging Research Group (CARG) score is an 11-item additive model developed for adults aged 65 years or older with solid tumors who were starting a new cytotoxic chemotherapy regimen. It combines age, cancer type, planned treatment, laboratory categories, and five geriatric-assessment responses.
The theoretical sum is 0-23. Observed scores in the 2011 derivation cohort reached 19; current ASCO/CARG materials group scores 10-23 as high. The displayed 30%, 52%, and 83% values are the observed derivation-cohort incidences of grade 3-5 chemotherapy toxicity for low, intermediate, and high groups, not individualized probabilities.
In the separate 2016 external-validation cohort, observed grade 3-5 toxicity was 36.7%, 62.4%, and 70.2% across the same groups. Those validation-cohort observations provide context and are not a second scoring model.
Primary Source EvidenceHurria A, Togawa K, Mohile SG, et al. J Clin Oncol. 2011;29(25):3457-3465. Hurria A, Mohile SG, Gajra A, et al. J Clin Oncol. 2016;34(20):2366-2371.
Formula Logic
Add the 11 source-defined predictor weights (0-23 points).

Reference Data

Risk groupScore2011 derivation-cohort incidence of grade 3-5 toxicity
Low Risk0-530%
Intermediate Risk6-952%
High Risk10-2383%

Clinical Workflow

Use, Interpret, And Continue The Patient Pathway

Expand for workflow guidance, limitations, examples, and related next steps.

When To Use

  • Use before a new cytotoxic chemotherapy regimen when all 11 source-defined categories are available.
  • Use only when the patient and clinical setting match the population described for CARG Chemotherapy Toxicity Score.

How To Interpret

  • Scores 0-5, 6-9, and 10-23 map to low, intermediate, and high groups; 30%, 52%, and 83% are derivation-cohort incidences rather than individualized probabilities.
  • Interpret thresholds with the entered units, current clinical status, and local guideline context.

What To Do Next

  • Review the complete geriatric assessment, clinical context, treatment goals, and patient preferences together with the score.
  • Document the inputs, result, clinical judgment, and any reason for deviating from the model-guided pathway.

Limitations

  • Use only in the studied setting of older adults with solid tumors starting a new cytotoxic chemotherapy regimen; the score does not prescribe a clinical action.
  • This calculator supports clinical assessment and does not independently prescribe treatment.

Validated Population

Adults aged 65 years or older with a solid tumor who are starting a new cytotoxic chemotherapy regimen

Clinical example

A total of 10 is in the high group and is contextualized by the derivation-cohort incidence, while decisions remain individualized.

Supportive care calculator hubReview toxicity, geriatric assessment, dosing, and supportive-care tools.CARG toxicity score guideReview the original model, validation, and clinical limitations.Geriatric toxicity calculator comparisonChoose among CARG, CARG-BC, CRASH, and G8 by clinical question.G8 geriatric screeningScreen for broader geriatric vulnerabilities before comprehensive assessment.CARG-BCUse the breast-specific model for its separate eligible population.Original CRASH 2012Review the separate three-output toxicity model when exact-regimen MAX2 is available.

Calculation verification history

Verified

  1. : Production browser revalidation

    • Three source-backed cases passed through all eleven visible production controls at scores 0, exact intermediate boundary 6, and maximum 23.
    • Low, Intermediate, and High groups matched the 0-5, 6-9, and 10-23 bands with 30%, 52%, and 83% clearly labeled as derivation-cohort incidences rather than individualized probabilities.
    • No unexpected N/A, stale control, literal undefined/null value, or browser-console error was observed.
    Download latest production check (Excel)

    Case-level evidence is retained in validation/browser-revalidation/carg-chemotherapy-toxicity-geriatric-assessment-2026-08-03.json.

  2. : Production browser validation

    • Ten source-backed cases were exercised on the public production route through visible browser controls; 10/10 case records passed their expected-versus-observed assertions across 11 visible submissions.
    • Overall browser status: failed-console. medium: Production emitted minified React error #418 during route loads/reloads used by this run.
    • Case-level inputs, expected and observed results, reset/repeat behavior, failure reproductions, and console evidence are retained in the production-browser evidence record.

    Case-level production evidence is retained in validation/browser-production/carg-chemotherapy-toxicity-geriatric-assessment.json.

  3. : Calculation verification

    • Implemented the original general 11-item additive model with exact source-defined weights and a theoretical total of 0-23.
    • Passed 228/228 all-total, predictor-weight, boundary, trace, strict invalid-input, no-default, and exact UI-serialization checks.
    • Separated 2011 derivation-cohort incidences from 2016 external-validation observations and retained the current 10-23 high group.

Verification confirms the calculator implementation against the cited model; it is not independent clinical validation, regulatory approval, or medical advice.

Found a possible issue? Report it to improve this calculator

Share This Calculator

Share:

Related Tools

G8 Screening ToolCARG-BC Breast Chemotherapy ToxicityOriginal CRASH Chemotherapy Toxicity Score (2012)

Frequently Asked Questions

Who is the original CARG score intended for?

Adults aged 65 years or older with solid tumors who are starting a new cytotoxic chemotherapy regimen and have all 11 source-defined inputs available.

Which factors are included in the CARG score?

The model uses age, cancer type, planned dose, number of cytotoxic drugs, hemoglobin, Jelliffe creatinine clearance using ideal weight, hearing, falls, walking limitation, medication management, and social-activity interference.

What outcome does the CARG score estimate?

It stratifies the observed incidence of grade 3-5 chemotherapy toxicity in the derivation cohort. The displayed percentages are group-level cohort observations, not individualized probabilities.

How is general CARG different from CARG-BC?

General CARG is an 11-item model for older adults with solid tumors starting cytotoxic chemotherapy. CARG-BC is a separate eight-item model for adults aged 65 or older with stage I-III breast cancer receiving neoadjuvant or adjuvant chemotherapy.

How is CARG different from G8?

CARG stratifies chemotherapy-toxicity risk in its studied population. G8 is a broader vulnerability screen that can support referral for comprehensive geriatric assessment.

Does a CARG result prescribe chemotherapy dose or treatment?

No. Interpret the score with comprehensive geriatric assessment, treatment goals, expected benefit, regimen options, supportive care, and patient preferences.

Evidence-based oncology decision support. Verify with clinical guidelines.